AMPLIFIER THERAPEUTICS Trademark

Trademark Overview


On Tuesday, January 3, 2023, a trademark application was filed for AMPLIFIER THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the AMPLIFIER THERAPEUTICS trademark a serial number of 97739348. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, July 2, 2024. This trademark is owned by Cambrian BioPharma, Inc.. The AMPLIFIER THERAPEUTICS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

research and development in the field of pharmacologic compounds affecting the cardiovascular system, pharmacologic compounds that produce the benefits of exercise, small molecules, and pharmacologic compounds affecting metabolic system; scientific research for medical purposes in the field of pharmacologic compounds affecting the cardiovascular system, pharmacologic compounds that produce the benefits of exercise, small molecules, and pharmacologic compounds affecting metabolic system

General Information


Serial Number97739348
Word MarkAMPLIFIER THERAPEUTICS
Filing DateTuesday, January 3, 2023
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, July 2, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 7, 2024

Trademark Statements


NOT AVAILABLE"THERAPEUTICS"
Goods and Servicesresearch and development in the field of pharmacologic compounds affecting the cardiovascular system, pharmacologic compounds that produce the benefits of exercise, small molecules, and pharmacologic compounds affecting metabolic system; scientific research for medical purposes in the field of pharmacologic compounds affecting the cardiovascular system, pharmacologic compounds that produce the benefits of exercise, small molecules, and pharmacologic compounds affecting metabolic system

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, January 26, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAMPLIFIER TX AB
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressUMEA 90326
SE

Party NameAMPLIFIER TX AB
Party Type11 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressUMEA 90326
SE

Party NameCambrian BioPharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10003

Trademark Events


Event DateEvent Description
Wednesday, July 26, 2023NON-FINAL ACTION E-MAILED
Friday, January 6, 2023NEW APPLICATION ENTERED
Thursday, January 26, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, May 3, 2023AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Friday, July 7, 2023ASSIGNED TO EXAMINER
Wednesday, July 26, 2023NON-FINAL ACTION WRITTEN
Wednesday, July 26, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, July 26, 2023NON-FINAL ACTION E-MAILED
Wednesday, July 26, 2023NON-FINAL ACTION WRITTEN
Wednesday, July 26, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, October 20, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Friday, October 20, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Friday, January 26, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, January 26, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, January 27, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 1, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 7, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, April 17, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 7, 2024PUBLISHED FOR OPPOSITION
Tuesday, July 2, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, December 18, 2024TEAS STATEMENT OF USE RECEIVED